Analysis of:
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease (www.fiercebiotech.com)
LY450139 acts through decrease the production of amyloid beta, the protein found in some of AD pathology. This novel mechanism of action carries the hope of halting disease progression.
Analysis of:
Merck, Schering Plunge as Doctors Discourage Vytorin (www.bloomberg.com)
Statins are the lipid lowering agents that decrease the incidence of heart attacks and stroke. The other lipide lowering agents, no matter how good the ads. and drug representatives tell you, is unclear
Analysis of:
Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial (www.pipelinereview.com)
In many respects, it is good that this trial was done. For many years, retinal physicians had used Avastin injections preferentially over Lucentis for the treatment of AMD because of the vast difference in cost.
Analysis of:
New Focus of Inquiry Into Bribes: Doctors (www.nytimes.com)
It is a common business practice for companies to wine and dine potential clients in an effort to secure new business contracts. This is not considered to be a bribe, it is considered good business practice. Is Stryker's case that different?
Physicians go into practice for many reasons. ...
Analysis of:
Rx Watchdog Report: Trends in Manufacturer Prices of Brand Name Prescription Drugs Used by Medicare Beneficiaries—2002-2007 (www.aarp.org)
As the population age, more and more patients depend on medicare for their medical care. I do not know how they are going to afford the medication cost with bad economy and elevated drug price
Analysis of:
R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 (www.pharmalive.com)
R & D investment from pharmaceuticals has been the main source of research in the development of new treatment
Analysis of:
Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain (www.pipelinereview.com)
Avaialbe treatments for diabetic neuropathy and other painful neuropathy are much improved over the last 10 years, but more effective ones are in great need
Analysis of:
Teva Provides Update on Glatiramer Acetate 40mg for Amyotrophic Lateral Sclerosis (pharmalive.com)
The phase II trial of Glatiramer acetate for ALS fail to show efficacy. This is not unexpected.
Analysis of:
FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder (pharmalive.com)
Luvox was one of the first SSRI's approved for pediatric prescription (for OCD rather than for depression). When patent expired, the maker discontinued manufacture. It has been available in limited supply as generic. Availability of brand-name extended-release product (Luvox CR) will be a significant...